Prescribing guide
Lumizyme (alglucosidase alfa)Dosing, infusion rate steps, CRIM and antibody monitoring, and prior authorization criteria for Pompe diseaseFor prescribers and their offices treating pompe disease: what the pharmacy needs before it ships, what the prior authorization wants documented, the titration and the monitoring the label requires.
Dispensing gate
No REMS (released August 1, 2014). Boxed warning: initiate in a healthcare setting with monitoring and access to CPR equipment. Prior authorization and a site of care before the first infusion; CRIM assessment early in IOPD.
Example PA threshold
Cigna example: Pompe disease; deficient GAA activity in blood, fibroblasts or muscle, or biallelic pathogenic or likely pathogenic GAA variants [documentation required]; specialist prescriber; dose not above 20mg/kg IV, no more often than every 2 weeks.
Monitoring
Supervised infusion with anaphylaxis readiness; vital signs at the end of each rate step; baseline ADA, then every 3 months (example) in year 1 for IOPD or within six months for LOPD; periodic urinalysis; extra monitoring in IOPD with cardiac or respiratory compromise.
Support line
CareConnect Case Managers 1-800-745-4447, option 3 (Monday to Friday 8 AM to 6 PM EST); Co-Pay Program 1-855-448-6520; Patient Assistance Program for uninsured or denied patients; Product Services option 1.
Give your patient their plan
A one-page handout for starting Lumizyme, in plain language: what the first fill waits on, the first dates, who will call and the symptoms to report, with blank lines for the start date and your office's number. The link opens the patient's full first 90 days page, where their dates become calendar entries.
trialfriend.com/p/lumizymeBefore the first fill: REMS, labs and enrollment
The steps that the pharmacy, the REMS or the drugmaker's program will wait on, in the order they usually need to happen. A first fill of a specialty drug most often stalls on one of these rather than on the plan.
| Step | What it requires | Source |
|---|---|---|
| Enroll in CareConnect | Send the patient or caregiver a digital consent link, or have them call a Case Manager at 1-800-745-4447 (English option 3, Spanish option 7). Lines are open Monday to Friday, 8 AM to 6 PM EST; or email info@CareConnectPSS.com. | CareConnect for HCPs |
| Ordering and delivery | Purchase through authorized distributors, specialty pharmacies or directly from Sanofi. Rare Disease Product Services, 1-800-745-4447 option 1 or CO@Sanofi.com, sends infusion and refill reminders and has after-hours on-call service. | CareConnect for HCPs |
| Confirm coverage and site of care | Sanofi advises confirming Lumizyme coverage before administration in LOPD, since more than one ERT is available. Check payer site of care, network provider and prior authorization rules. | Lumizyme billing guide |
| Statement of medical necessity | Sanofi's sample form asks for reduced or absent GAA enzyme activity with sample type, or GAA gene sequencing, plus weight, dose and frequency. Attach the assay or sequencing report. | Lumizyme billing guide |
| Calculate vials | 50mg single-dose vials, cartons of 1 (NDC 58468-0160-1) or 10 (NDC 58468-0160-2), refrigerated at 2°C to 8°C. Vials from actual body weight at 20mg/kg, rounded up to the next whole number. | FDA label |
| Reconstitute | Let vials sit about 30 minutes at room temperature. Inject 10.3mL Sterile Water for Injection slowly down the inside wall; tilt and roll, do not invert, swirl or shake; yields 5mg/mL, 50mg per 10mL extractable. No filter needles. | FDA label |
| Dilute | 0.9% Sodium Chloride to the Table 1 total volume by weight (25mL at 1.25 to 2.5kg, up to 1,000mL at 180.1 to 200kg); final 0.5 to 4mg/mL. Remove bag airspace; do not shake. Up to 24 hours at 2°C to 8°C, protected from light. | FDA label |
| Billing codes | HCPCS J0221, injection, alglucosidase alfa (Lumizyme), 10mg. ICD-10-CM E74.02 for IOPD or LOPD. CPT 96365 and 96366 are the infusion codes Sanofi lists. | Lumizyme billing guide |
| Co-Pay Program | Commercial only: 100% of eligible out-of-pocket drug costs up to a program maximum. Excludes Medicaid, Medicare, VA, DoD, TRICARE and other federal or state programs. Infusion-related costs not covered in MA or RI. Runs January 1 to December 31. Fax 1-800-750-9839; questions 1-855-448-6520. | Co-Pay Program application |
| Patient Assistance Program | Certain Sanofi therapies at no cost for eligible patients without insurance or who cannot access the product under their plan. Sanofi describes it as temporary until coverage is secured. | CareConnect for HCPs |
Prior authorization criteria and what to document
One public policy as the example: Cigna, August 15, 2026. Approval one year. This policy (Drug Coverage Policy IP0440) added documentation requirements on August 15, 2026. It cites the December 2024 label, which is the current FDA-approved text. It is here as an example of what a plan asks for, not as a rule.
| Element | What the policy asks | In the chart | Source |
|---|---|---|---|
| Indication | Acid alpha-glucosidase deficiency (Pompe disease); no age or onset-type criterion | Diagnosis in the note | Cigna policy |
| Diagnosis, enzyme route | Laboratory test demonstrating deficient acid alpha-glucosidase activity in blood, fibroblasts or muscle tissue [documentation required] | Enzyme assay report | Cigna policy |
| Diagnosis, genetic route | Molecular genetic test demonstrating biallelic pathogenic or likely pathogenic GAA variants [documentation required]; either route qualifies | Genetic test report | Cigna policy |
| Prescriber | Geneticist, neurologist, metabolic disorder sub-specialist or physician who specializes in lysosomal storage disorders, or in consultation with one | Prescriber specialty or consult note | Cigna policy |
| Dosing | Each dose must not exceed 20mg/kg IV no more frequently than once every 2 weeks. Other doses case by case | Order with current weight | Cigna policy |
| Approval | 1 year; extended approvals if criteria and dosing still met | Updated criteria at each review | Cigna policy |
Lumizyme dosing and titration
| When | Label | Source |
|---|---|---|
| Dose | 20mg/kg body weight every 2 weeks by IV infusion, IOPD and LOPD. Total volume over approximately 4 hours. | FDA label |
| Rate steps | Initial rate no more than 1mg/kg/hour. May increase by 2mg/kg/hour every 30 minutes once tolerance is established, to a maximum of 7mg/kg/hour. Vital signs at the end of each step. | FDA label |
| Administration set | Infusion pump; in-line low protein binding 0.2 micron filter. Do not infuse in the same line with other products. Sanofi notes filters are not in the product package. | Lumizyme dosing page (HCP) |
| Before infusion | Consider pretreating with antihistamines, antipyretics and/or corticosteroids. Supervision by a provider knowledgeable in managing hypersensitivity including anaphylaxis; CPR equipment readily available. | FDA label |
| Mild or moderate reaction | Consider temporarily holding the infusion or slowing the rate. For IARs, antihistamines and/or antipyretics may ameliorate symptoms; monitor closely on re-administration. | FDA label |
| Severe reaction | Discontinue and immediately initiate treatment, including epinephrine. Weigh readministration; rechallenge may use slower rates at a lower dosage than recommended. | FDA label |
| Missed dose | If one or more doses are missed, restart as soon as possible, then keep the 2 week interval. | FDA label |
| Vial example | Sanofi example: 68kg x 20mg/kg = 1,360mg; 27.2 vials rounded up to 28. Dosing questions: Sanofi Medical Information, 800-745-4447, option 2. | Lumizyme dosing page (HCP) |
| Pediatric, renal, hepatic | Safety and effectiveness established in pediatric patients; IOPD trials enrolled ages 0.2 month to 3.5 years. The label has no renal or hepatic impairment section. | FDA label |
Monitoring the Lumizyme label requires
| When | What | What the label says to do with it | Source |
|---|---|---|---|
| Each infusion and up to 3 hours after | Hypersensitivity including anaphylaxis; some reactions IgE-mediated | If severe, discontinue and treat, including epinephrine. Monitor IgE-positive patients more closely | FDA label |
| Each rate step | Vital signs at the end of each step | Increase only once tolerance is established; continue at 7mg/kg/hour if stable | FDA label |
| Early in IOPD | CRIM assessment | CRIM-negative status is a risk factor for high sustained ADA titers; manage with a specialist in immune tolerance induction | FDA label |
| Baseline, then during treatment | ADA titers. IOPD: regularly in year 1 (example: every 3 months). LOPD: within six months, then as clinically warranted | Hypersensitivity: consider IgG ADA, IgE ADA and other mediators. Reduced response: consider IgG ADA and inhibitory antibody activity. ADA testing information: 1-800-745-4447 | FDA label |
| Ongoing | Systemic immune-mediated reactions involving skin and other organs, including periodic urinalysis | Seen several weeks to 3 years after initiation. Consider discontinuing and treating; weigh readministration | FDA label |
| Each infusion, at-risk patients | Acute respiratory illness or compromised cardiac and/or respiratory function; IOPD with cardiac hypertrophy | Additional monitoring; some patients need prolonged, individualized observation | FDA label |
| Central line placement | General anesthesia in IOPD with cardiac hypertrophy | Ventricular arrhythmias and bradycardia with cardiac arrest or death have occurred; use caution | FDA label |
| Ongoing | Pompe Registry, including pregnancy exposure | registrynxt.com or 1-800-745-4447, extension 15500 | FDA label |
Lumizyme drug interactions and contraindications
| Label category | Agents and what the label says | Source |
|---|---|---|
| Contraindications | None | FDA label |
| Drug interactions | The label has no drug interactions section; do not infuse in the same IV line with other products | FDA label |
| Pregnancy | Postmarketing and published case reports have not identified a drug-associated risk of major birth defects, miscarriage or adverse outcomes. Individualize continuation; untreated disease may worsen respiratory and musculoskeletal symptoms | FDA label |
| Lactation | Published literature suggests presence in human milk; no reports of adverse effects on the breastfed infant. A woman may consider pumping and discarding milk during treatment and for 24 hours after | FDA label |
| Geriatric | The placebo-controlled study included 4 patients aged 65 and over, too few to determine whether response differs | FDA label |
Why a first fill stalls, and the fix
- Prior authorization pending or deniedThe Cigna policy below asks for a lab report showing low GAA enzyme activity in blood, skin cells or muscle, or a genetic test showing changes in both GAA genes.
- The doctor is not a specialistCigna asks that Lumizyme be prescribed by, or with advice from, a geneticist, neurologist, metabolic specialist or lysosomal storage disorder specialist.
- A dose outside the plan's limitCigna approves doses up to 20mg/kg by IV, no more often than once every 2 weeks, and other doses are reviewed case by case.
- The plan covers a different Pompe medicineSanofi tells doctors to confirm Lumizyme coverage with the plan before an infusion in late-onset disease, because more than one enzyme replacement therapy exists.
- The plan limits where infusions happenSanofi says some plans have site of care rules or contracts with certain providers. Your doctor's office or a CareConnect Case Manager can check before the first infusion.
- A copay you cannot payCommercial insurance: the Co-Pay Program pays 100% of eligible out-of-pocket drug costs up to a program maximum. Medicare, Medicaid, VA, TRICARE and other government coverage are excluded.
- A new calendar yearThe Co-Pay Program runs from January 1 through December 31. Sanofi says you may need to re-enroll each year to confirm you still qualify.
- No insurance, or the plan will not cover itThe CareConnect Patient Assistance Program may provide Lumizyme at no cost. Sanofi calls it a temporary solution until coverage can be secured, and Case Managers are at 1-800-745-4447, option 3.
CareConnect Personalized Support Services
- A Case Manager for insurance, financial help, care coordination and life changes such as travel, moving or new insurance, with Spanish at option 7
- A Patient Education Liaison for disease, treatment and inheritance education. Families and caregivers may take part too
- Patient Education Liaisons have a clinical background in nursing or genetic counseling, and Case Managers can explore options if you have no insurance CareConnect services page
- The Co-Pay Program for commercial insurance, paying 100% of eligible out-of-pocket drug costs up to a program maximum, with questions answered at 1-855-448-6520 Co-Pay Program application
- Co-pay help is not open to people whose prescriptions are paid by Medicare, Medicaid, VA, Department of Defense, TRICARE or other federal or state programs
- The Patient Assistance Program, certain Sanofi therapies at no cost for eligible people without insurance or whose plan will not cover them
- Help finding treatment centers and home infusion resources when you travel or move
Questions prescribers' offices ask about Lumizyme
What is the Lumizyme dose for Pompe disease?
The December 2024 label (DailyMed version 21, January 2025) sets 20mg/kg body weight every 2 weeks by IV infusion for all patients with Pompe disease, IOPD and LOPD. Vials hold 50mg; calculate from actual body weight and round up to the next whole vial. The total volume is given over approximately 4 hours.
What are the Lumizyme infusion rate steps?
The December 2024 label starts at no more than 1mg/kg/hour, then allows increases of 2mg/kg/hour every 30 minutes, to 3, 5 and a maximum of 7mg/kg/hour, once tolerance is established. Obtain vital signs at the end of each step. Use an infusion pump and an in-line low protein binding 0.2 micron filter. Table 1 gives mL/hour by weight band.
What antibody monitoring does the Lumizyme label recommend?
Section 5.6 of the December 2024 label strongly encourages a baseline serum ADA sample before the first infusion. For IOPD it suggests regular ADA monitoring during the first year (example: every 3 months). For LOPD it suggests ADA within six months of initiation, then as clinically warranted. Genzyme gives ADA testing information at 1-800-745-4447.
When is CRIM testing needed with Lumizyme?
The December 2024 label says patients with IOPD should have a CRIM assessment early in their disease course. CRIM-negative infants with high sustained IgG ADA titers and positive inhibitory antibodies showed poorer clinical response. These patients must be managed by a clinical specialist knowledgeable in immune tolerance induction in Pompe disease.
What are the Lumizyme prior authorization criteria?
The Cigna policy shown here, IP0440 effective August 15, 2026, approves 1 year for Pompe disease with no age criterion. Diagnosis needs deficient GAA activity in blood, fibroblasts or muscle, or biallelic pathogenic or likely pathogenic GAA variants, each with documentation. It also requires a specialist prescriber and doses not above 20mg/kg every 2 weeks.
Free email alert
Get an email when the Lumizyme label changes
One email the day the FDA revises the Lumizyme prescribing information, with a summary of what changed. No trial alerts or newsletter, and you can stop anytime.
Label changes for Lumizyme only, usually a few a year and some years none. Stop anytime. We never share your email. Privacy policy
Sources
- LUMIZYME (alglucosidase alfa), for injection, for intravenous use, prescribing information, Revised 12/2024 (DailyMed version 21, updated January 10, 2025), Genzyme Corporation, via DailyMed and openFDA, 2025-01-10.
- Lumizyme | Patients & Families, Sanofi, 2025-03.
- Lumizyme® Dosing and Administration | For US HCPs, Sanofi, 2025-09.
- Lumizyme® (alglucosidase alfa) Billing and Coding Guide for Reimbursement (MAT-US-2002147-v5.0-06/2026), Sanofi, 2026-06.
- CareConnect for Healthcare Professionals, Sanofi, 2024-11.
- Our Services and Team | Sanofi CareConnect, Sanofi, 2025-11.
- CareConnect Personalized Support Services Co-Pay Program Application, Enzyme Replacement Therapies (MAT-US-2506611-v1.0-06/2025), Sanofi, 2025-06.
- Pompe Disease – Enzyme Replacement Therapy – Lumizyme, Drug Coverage Policy IP0440, Cigna, 2026-08-15.
- BLA 125291/S-161 supplement approval letter, Lumizyme (alglucosidase alfa), immunogenicity labeling update, FDA, 2024-12-30.
- BLA 125291/S-160 supplement approval letter, Lumizyme (alglucosidase alfa), new warning for infusion-associated reactions, FDA, 2024-03-22.
- BLA 125291/S-159 supplement approval letter, Lumizyme (alglucosidase alfa), adverse reactions update, FDA, 2023-05-24.
- BLA 125291/136 supplement approval and release of REMS requirement letter, Lumizyme (alglucosidase alfa), FDA, 2014-08-01.
- BL 125291/0 BLA approval letter, Lumizyme (alglucosidase alfa), FDA, 2010-05-24.
A reference drawn from the January 10, 2025 label, the drugmaker's published program and one public insurer policy shown as an example, checked on November 11, 2026. Labels and policies change; the label on DailyMed and the plan's current policy govern. Trial Friend is not a medical provider. It reports what these documents say and does not judge whether a drug is safe or right for any patient; that is the prescriber's decision. Not a substitute for the prescribing information.